<DOC>
	<DOCNO>NCT02095756</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety combination non-hydroquinone topical therapy 755nm Alexandrite compare topical therapy alone treatment facial melasma .</brief_summary>
	<brief_title>Combination Alexandrite Laser Topical Therapy v Topical Therapy Alone Treatment Melasma</brief_title>
	<detailed_description />
	<mesh_term>Melanosis</mesh_term>
	<criteria>Male female Subjects age 1874 year age ; Fitzpatrick Skin Types IIV ; Female subject childbearing potential must negative urine pregnancy test beginning study , agree practice appropriate birthcontrol prevent pregnancy study . The type dose birth control must stable least 3 month prior study entry expect change study ; acceptable method birth control oral contraceptive , contraceptive patches/rings/implants Norplant® , DepoProvera® , doublebarrier method ( e.g . condom spermicide ) , abstinence vasectomy partner document second acceptable method birth control subject become sexually active . Subjects diagnose moderate severe melasma side face For subject use medication treat concurrent medical condition , type dose must stable least 3 month prior study entry expect change study ( except medication specifically outline exclusion criterion section ) Subjects able avoid prolong sun exposure face duration study willing use appropriate sun avoidance technique . Subjects able follow study instruction likely complete require visit ; Subjects/Representative able willing sign Informed Consent ( include photography release ) prior study procedure . Female subject pregnant , nurse plan pregnancy course study ; Subjects condition situation , Investigator 's opinion , may put Subject risk , may confound study result , may interfere Subject 's participation study , : use concomitant medication interfere study worsen condition use study , use medication know induce photosensitivity ; Subjects treatment dermatologic condition , may interfere safe evaluation study regimen ( e.g . eczema , psoriasis , severe sundamage , dermatitis ) and/or scar infection area treat ; Subjects diagnosis skin cancer ( BCE , SCC , Melanoma , etc . ) area treat ; Subject unwilling avoid treatment melasma study ( total duration 30 week ) ; Subjects washout period le 14 day melasma treatment time study entry current treatment ; Subjects prior facial resurfacing , deep chemical peel within 6 month date study entry ; Subject unwilling refrain facial cosmetic procedure study period ( e.g. , chemical peel , resurface , microdermabrasion , etc . ) ; Subject initiate treatment hormone include estrogen , progesterone and/or oral contraceptive within 3 month study entry , intend discontinue hormonal therapy study ; Subject participate clinical research study within last 30 day prior enrollment ; Subject unable communicate cooperate Investigator due language problem , poor mental development , reason ; Subject unable meet study attendance requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>